Patent Grant
11123312
Serious spinal cord injuries (SCI) affect approximately 1.3 million people in the United States, and roughly 12-15,000 new injuries occur each year. Of these injuries, approximately 50% are complete spinal cord injuries in which there is essentially total loss of sensory motor function below the level of the spinal lesion.
Paralysis of the upper limbs results in an enormous loss of independence of one's daily life. Meaningful improvement in hand function is generally rare after one year of tetraparesis.
In various embodiments, methods are provided for applying spinal cord stimulation with and without selective pharmaceuticals to restore voluntary control of hand function in tetraplegic subjects. The spinal cord stimulation can be transcutaneous and/or epidural. In various embodiments the electrical stimulation alone or in combination with pharmaceuticals can be applied to facilitate restoration of motor control and/or force generation in subjects suffering with spinal cord injury and/or as other neurological injury and illness that effects motor control of the hand or paw. Successful application can provide a device for widespread use in rehabilitation of neurologic injury and disease.
In particular illustrative embodiments, the devices, optional pharmacological agents, and methods described herein stimulate the spinal cord with, e.g., electrodes that modulate the proprioceptive and supraspinal information that controls the hands during reaching and/or grasping and/or manipulating conditions. Without being bound by a particular theory, it is believed the proprioceptive and cutaneous sensory information guides the activation of the muscles in a coordinated manner and in a manner that accommodates the external conditions.
Unlike approaches that involve specific stimulation of motor neurons to directly induce a movement, the methods described herein can enable the spinal circuitry to control the movements. More specifically, the devices, optional pharmacological agents, and methods described herein can exploit the spinal circuitry and its ability to interpret proprioceptive information and to respond to that proprioceptive information in a functional way. In various embodiments, this is in contrast to other approaches where the actual movement is induced/controlled by direct stimulation (e.g., of particular motor neurons).
Accordingly, in various aspects, the invention(s) contemplated herein may include, but need not be limited to, any one or more of the following embodiments:
A method of improving motor control and/or strength in a hand of a subject with a neuromotor disorder affecting motor control of the hand, said method including: neuromodulating the cervical spinal cord of the subject by administering stimulation to the cervical spinal cord or a region thereof; and by administering to the subject at least one monoaminergic agonist. In some instances of Embodiment 1, the spinal cord stimulation can be transcutaneous and/or epidural.
The method of embodiment 1, wherein said method includes administering transcutaneous stimulation to the cervical spinal cord or a region thereof.
The method of embodiment 1, wherein said method includes administering epidural stimulation to the cervical spinal cord or a region thereof.
The method of embodiment 1, wherein said method includes administering a monoaminergic agonist to said subject.
The method of embodiment 1, wherein said method includes administering transcutaneous stimulation to the cervical spinal cord or a region thereof in conjunction with administration of a monoaminergic agonist.
The method of embodiment 1, wherein said method includes administering epidural stimulation to the cervical spinal cord or a region thereof in conjunction with administration of a monoaminergic agonist.
The method of embodiment 1, wherein said method includes administering transcutaneous stimulation to the cervical spinal cord or a region thereof in conjunction with epidural stimulation of the cervical spinal cord or a region thereof.
The method of embodiment 1, wherein said method includes administering transcutaneous stimulation to the cervical spinal cord or a region thereof in conjunction with epidural stimulation of the cervical spinal cord or a region thereof in conjunction with administration of a monoaminergic agonist to said subject.
The method according to any one of embodiments 1, 2, 5, 7, and 8, wherein said transcutaneous stimulation is at a frequency ranging from about 3 Hz, or from about 5 Hz, or from about 10 Hz to about 100 Hz, or to about 80 Hz, or to about 40 Hz, or from about 3 Hz or from about 5 Hz to about 80 Hz, or from about 5 Hz to about 30 Hz, or to about 40 Hz, or to about 50 Hz.
The method according to any one of embodiments 1, 2, 5, and 7-9, wherein said transcutaneous stimulation is applied at an intensity ranging from about 10 mA to about 150 mA, or from about 20 mA to about 50 mA or to about 100 mA, or from about 20 mA or from about 30 mA, or from about 40 mA to about 50 mA, or to about 60 mA, or to about 70 mA or to about 80 mA.
The method according to any one of embodiments 1, 2, 5, and 7-10, wherein said transcutaneous stimulation is at a frequency and amplitude sufficient to improve hand strength and/or fine hand control.
The method according to any one of embodiments 1, 2, 5, and 7-11, wherein said transcutaneous stimulation is applied to the dorsal aspect of the neck in the area of C5.
The method according to any one of embodiments 1, 3, and 6-12, wherein said epidural stimulation is at a frequency ranging from about 3 Hz, or from about 5 Hz, or from about 10 Hz to about 100 Hz, or to about 80 Hz, or to about 40 Hz, or from about 3 Hz or from about 5 Hz to about 80 Hz, or from about 5 Hz to about 30 Hz, or to about 40 Hz, or to about 50 Hz.
The method according to any one of embodiments 1, 3, and 6-13, wherein said epidural stimulation is at an amplitude ranging from 0.05 mA to about 30 mA, or from about 0.1 mA to about 20 mA, or from about 0.1 mA to about 15 mA or to about 10 mA.
The method according to any one of embodiments 1, 3, and 6-14, wherein said pulse width ranges from about 150 μs to about 600 μs, or from about 200 μs to about 500 μs, or from about 200 μs to about 450 μs.
The method according to any one of embodiments 1, 3, and 6-15, wherein said epidural stimulation is at a frequency and amplitude sufficient to improve hand strength and/or fine hand control.
The method according to any one of embodiments 1, 3, and 6-16, wherein said epidural stimulation is applied paraspinally over vertebrae spanning C2 to T1.
The method according to any one of embodiments 1, 3, and 6-16, wherein said epidural stimulation is applied paraspinally over vertebrae spanning C5 to T1.
The method according to any one of embodiments 1, 3, and 6-18, wherein said epidural stimulation is applied via a permanently implanted electrode array.
The method of embodiment 19, wherein said electrode array is a parylene based microelectrode implant.
The method according to any one of embodiments 1, 4, 5, 6, and 8-20, wherein the at least one monoaminergic agonist includes a drug selected from the group consisting of a serotonergic drug, a dopaminergic drug, a noradrenergic drug, a GABAergic drug, and a glycinergic drug.
The method of embodiment 21, where the agent is selected from the group consisting of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), 4-(benzodioxan-5-yl)1-(indan-2-yl)piperazine (S15535), N-{2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl}-N-(2-pyridinyl)cyclo-hexanecarboxamide (WAY 100.635), Quipazine, Ketanserin, 4-amino-(6-chloro-2-pyridyl)-1 piperidine hydrochloride (SR 57227A), Ondanesetron, Buspirone, Methoxamine, Prazosin, Clonidine, Yohimbine, 6-chloro-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol (SKF-81297), 7-chloro-3-methyl-1-phenyl-1,2,4,5-tetrahydro-3-benzazepin-8-ol (SCH-23390), Quinpirole, and Eticlopride.
The method of embodiment 21, wherein said monoaminergic agonist is buspirone.
The method of embodiment 22, wherein said drug is 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT).
The method of embodiment 22, wherein said drug is 4-(benzodioxan-5-yl)1-(indan-2-yl)piperazine (S15535).
The method of embodiment 22, wherein said drug is N-{2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl}-N-(2-pyridinyl)cyclo-hexanecarboxamide (WAY 100.635).
The method of embodiment 22, wherein said drug is Quipazine.
The method of embodiment 22, wherein said drug is Ketanserin.
The method of embodiment 22, wherein said drug is 4-amino-(6-chloro-2-pyridyl)-1 piperidine hydrochloride (SR 57227A).
The method of embodiment 22, wherein said drug is Ondanesetron.
The method of embodiment 22, wherein said drug is Methoxamine.
The method of embodiment 22, wherein said drug is Prazosin.
The method of embodiment 22, wherein said drug is Clonidine.
The method of embodiment 22, wherein said drug is Yohimbine.
The method of embodiment 22, wherein said drug is 6-chloro-1-phenyl-2.
The method of embodiment 22, wherein said drug is 3,4,5-tetrahydro-1H-3-benzazepine-7.
The method of embodiment 22, wherein said drug is 8-diol (SKF-81297).
The method of embodiment 22, wherein said drug is 7-chloro-3-methyl-1-phenyl-1,2,4,5-tetrahydro-3-benzazepin-8-ol (SCH-23390).
The method of embodiment 21, wherein said drug is Quinpirole.
The method of embodiment 21, wherein said drug is and Eticlopride.
The method according to any one of embodiments 1 and 4-40, wherein a combination of transcutaneous and/or epidural stimulation and monoaminergic agonist provides a synergistic improvement in hand strength and/or fine hand control.
The method according to any one of embodiments 1-41, wherein said subject is a human. In some embodiments, the subject is a non-human mammal.
The method according to any one of embodiments 1-42, wherein said subject has a spinal cord injury.
The method of embodiment 43, wherein said spinal cord injury is clinically classified as motor complete.
The method of embodiment 43, wherein said spinal cord injury is clinically classified as motor incomplete.
The method according to any one of embodiments 1-42, wherein said subject has an ischemic brain injury.
The method of embodiment 46, wherein said ischemic brain injury is brain injury from stroke or acute trauma.
The method according to any one of embodiments 1-42, wherein said mammal has a neurodegenerative pathology.
The method of embodiment 48, wherein said neurodegenerative pathology is associated with a condition selected from the group consisting of Parkinson's disease, Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), primary lateral sclerosis (PLS), dystonia, and cerebral palsy.
The method according to any one of embodiments 1-49, wherein the stimulation is under control of the subject.
The method according to any one of embodiments 1-50, wherein said method further includes physical training of said subject.
The method of embodiment 51, wherein said physical training includes hand contraction against a resistance.
The method according to any one of embodiments 51-52, wherein said physical training includes tracing a displayed pattern by hand manipulation of a hand controller.
An electrical stimulator configured to induce epidural and/or transcutaneous electrical stimulation in the cervical region of a mammal according to any one of embodiments 1-20.
As used herein “electrical stimulation” or “stimulation” means application of an electrical signal that may be either excitatory or inhibitory to a muscle or neuron and/or to groups of neurons and/or interneurons. It will be understood that an electrical signal may be applied to one or more electrodes with one or more return electrodes.
As used herein “epidural” means situated upon the dura or in very close proximity to the dura. The term “epidural stimulation” refers to electrical epidural stimulation. In certain embodiments epidural stimulation is referred to as “electrical enabling motor control” (eEmc).
The term “transcutaneous stimulation” or “transcutaneous electrical stimulation” or “cutaneous electrical stimulation” refers to electrical stimulation applied to the skin, and, as typically used herein refers to electrical stimulation applied to the skin in order to effect stimulation of the spinal cord or a region thereof. The term “transcutaneous electrical spinal cord stimulation” may also be referred to as “tSCS”. The term “pcEmc” refers to painless cutaneous electrical stimulation.
The term “motor complete” when used with respect to a spinal cord injury indicates that there is no motor function below the lesion, (e.g., no movement can be voluntarily induced in muscles innervated by spinal segments below the spinal lesion.
The term “monopolar stimulation” refers to stimulation between a local electrode and a common distant return electrode.
The term “co-administering”, “concurrent administration”, “administering in conjunction with” or “administering in combination” when used, for example with respect to transcutaneous electrical stimulation, epidural electrical stimulation, and pharmaceutical administration, refers to administration of the transcutaneous electrical stimulation and/or epidural electrical stimulation and/or pharmaceutical such that various modalities can simultaneously achieve a physiological effect on the subject. The administered modalities need not be administered together, either temporally or at the same site. In some embodiments, the various “treatment” modalities are administered at different times. In some embodiments, administration of one can precede administration of the other (e.g., drug before electrical stimulation or vice versa). Simultaneous physiological effect need not necessarily require presence of drug and the electrical stimulation at the same time or the presence of both stimulation modalities at the same time. In some embodiments, all the modalities are administered essentially simultaneously.
Embodiments described herein provide methods for applying spinal cord stimulation with and without selective pharmaceuticals to restore voluntary control of upper extremity function in tetraplegic subjects. In some embodiments, the upper extremity or extremities can be the hands. The spinal cord stimulation can be transcutaneous, epidural, or a combination thereof. The spinal cord stimulation alone or in combination with pharmaceuticals can be applied to facilitate restoration of motor control and/or force generation in individuals with spinal cord injuries.
As demonstrated herein in the Examples, an injured cervical spinal cord (e.g., a human cervical spinal cord) can be modulated using painless cutaneous electrical stimulation (pcEmc), monoaminergic agonist (fEmc) treatment, and/or eEmc to regain voluntary hand function. In some embodiments, mean hand strength can be increased by greater than 300% after pcEmc plus fEmc (buspirone) treatment. This was demonstrated in 6 subjects with a chronic motor complete cervical injury. One subject that was implanted with a cervical epidural electrode array realized significantly improved hand strength and fine hand control in the presence of cervical eEmc. Thus, the cervical circuitry can be neuromodulated to improve volitional control of hand function in tetraplegic subjects with one or more interventions: transcutaneous electrical stimulation (e.g., pcEMC), and/or monoaminergic agonist administration (fEmc), and/or epidural electrical stimulation (eEmc). In some embodiments, the impact of the herein described methods on individuals with upper limb paralysis can be dramatic functionally, psychologically, and economically.
Accordingly, in various embodiments, methods are provided for improving motor control and/or strength in a hand (or paw) of a subject with a neuromotor disorder affecting motor control of the hand (or paw). In various embodiments, the methods involve neuromodulating the cervical spinal cord of the subject by administering transcutaneous stimulation to the cervical spinal cord or a region thereof; and/or neuromodulating the cervical spinal cord of said subject by administering epidural stimulation to the cervical spinal cord or a region thereof; and/or by administering to the subject a monoaminergic agonist (or other neuromodulatory pharmaceutical).
In some embodiments, neuromodulatory strategies can be used to improve fine motor control of the upper limbs, i.e., performance of motor tasks considered to be less “automatic” than posture and locomotion. These strategies can neuromodulate the lumbosacral spinal circuitry via epidural stimulation (electrical enabling motor control, eEmc)
In various embodiments, these methods can, optionally, be used in combination with physical training regimen. And in some embodiments, the pharmaceutical can be buspirone.
The methods described herein are for use with a mammal (e.g., a human, a mamal (e.g., a non-human primate, equine, feline, canus, etc.) who has a spinal cord with at least one dysfunctional spinal circuit that inhibits motor control and/or strength in a hand or paw and/or who exhibits another neuropathology that inhibits motor control and/or strength in a hand or paw. In one embodiment, the mammal is a human. As described herein, ranscutaneous electrical stimulation of the cervical spinal cord or a region thereof, and/or epidural stimulation of the cervical spinal cord, or a region thereof, and/or use of a neuromodulatory agent (e.g., a monoaminergic agent) can improve and/or restore motor control and/or strength to a hand or paw.
In some embodiments, hand function can be improved by neuromodulating the cervical spinal cord. Six subjects with chronic (18-36 months) spinal cord injury (SCI, traumatic cervical injury, ASIA B with no motor strength below the injury) were tested. All subjects initially had minimal hand strength, a condition characteristic of the majority of cervical SCI patients. The experimental approach began with six weeks of baseline testing (Phase 1), followed by three 2-week treatment periods (phases 2-4), and then by a period of approximately three months without any treatment at the end of which there was a final two week testing period (Phase 5). pcEmc at the C5 spinal segment (Phase 2) increased hand strength in 4/6 subjects compared to baseline Phase 1. During buspirone treatment (Phase 3), 4/6 subjects increased hand strength compared to Phase 1 and 2. The next 2 weeks buspirone was withdrawn but pcEmc continued (Phase 4), and again 4/6 subjects showed further improvement in grip strength compared to Phase 3. For all subjects combined, the mean grip strength tended to increase after each successive treatment phase. EMG amplitudes were generally consistent with increases in grip force, i.e., digit flexor and extensor EMG amplitudes tended to increase progressively across phases. After approximately three months without treatment, 4/6 subjects improved their performance relative to Phase 4.
These results show that the cervical spinal cord can be neuromodulated using two paradigms, i.e., electrically and pharmacologically. Moreover, these data indicate that non-functional networks can become engaged and progressively improve motor performance. In addition, the further improvement in hand function after withdrawing pcEMC and fEMC suggests that once functional connections are established they remain active.
Accordingly, the methods described herein are useful to improve and/or restore motor function to the hand or paw of a subject having paralysis affecting that hand or paw. In various embodiments, the methods provide that the spinal circuitry is neuromodulated to a physiological state that facilitates or enables the recovery or improved control of movement or improved strength of a hand or paw following some neuromotor dysfunction.
In some embodiments the paralysis effecting the hand or paw may be a motor complete paralysis or a motor incomplete paralysis. In certain embodiments the paralysis may have been caused by a spinal cord injury classified as motor complete or motor incomplete. The paralysis may have been caused by an ischemic or traumatic brain (or spinal) injury. In certain embodiments the paralysis may have been caused by an ischemic brain injury resulting from a stroke or acute trauma. By way of another example, the paralysis may have been caused by a neurodegenerative condition affecting the brain and/or spinal cord. In certain embodiments the neurodegenerative injury may be associated with a disease such as Parkinson's disease, Huntington's disease, Alzheimer's disease, frontotemporal dementia, dystonia, amyotrophic lateral sclerosis (ALS), primary lateral sclerosis (PLS), and other conditions such as cerebral palsy and multiple sclerosis (MS).
By way of non-limiting example, in certain embodiments, the methods described herein comprises application of electrical stimulation to the cervical spinal cord or a portion thereof of the subject. The electrical stimulation may be applied by a surface electrode(s) that is applied to the skin surface of the subject to provide a transcutaneous stimulation. Additionally, or alternatively, the electrical stimulation can be provided epidurally (e.g., via an implanted electrode or electrode array).
In various embodiments, the electrodes may; be implanted along, and/or the stimulation may be applied to the entire cervical spine (e.g., C1-T1) or to a region therein (e.g., C2-C7, C3-C7, C3-C6, C3-C5, C4-C7, C4-C6, C4-C5, C5, etc.). The electrical stimulation is delivered, e.g., as described herein (e.g., at 5-40 Hz at 20-100 mA). While not a requirement, the electrical stimulation may not directly activate muscle cells in the portion of the patient's body having the paralysis. In certain embodiments the electrodes (surface and/or implanted) may include an array of one or more electrodes stimulated in a monopolar biphasic configuration.
In various embodiments, the stimulation may include tonic stimulation and/or intermittent stimulation. The stimulation may include simultaneous or sequential stimulation, or combinations thereof, of different cord regions (e.g., different regions within the cervical spinal cord, or a region within the cervical spinal cord and another regions outside the cervical spinal cord). Optionally, in certain embodiments, the stimulation pattern may be under control of the subject.
In certain embodiments, the method(s) may include administering one or more neuropharmaceutical agents to the subject. The neuropharmaceutical agents may include, for example, a monoaminergic agent (e.g., buspirone).
In certain embodiments, the electrical stimulation is defined by a set of parameter values (e.g., frequency, amplitude, pulse width, etc.), and activation of the selected spinal circuit may (but need not) generate a quantifiable result. Optionally, the method may be repeated using electrical stimulation having different sets of parameter values to obtain quantifiable results generated by each repetition of the method. In certain embodiments a machine learning method may be executed by at least one computing device. The machine learning method builds a model of a relationship between the electrical stimulation applied to the spinal cord and the quantifiable results generated by activation of the at least one spinal circuit. A new set of parameters may be selected based on the model. By way of a non-limiting example, the machine learning method may implement a Gaussian Process Optimization, e.g., as described in PCT Publication No: WO/2012/094346 (PCT/US2012/020112).
In various embodiments, the methods described herein may further incorporate physical training. In certain embodiments, the physical training may include inducing a resistance-providing positional change in the region of the subject where locomotor activity is to be facilitated (e.g., the hand and/or finger(s)). The positional change in the subject may include, but need not be limited to grasping and/or tracking. In certain embodiments, the physical training may include robotically guided training.
Another exemplary embodiment is a method that includes placing an electrode on the subject's cervical spinal cord, positioning the patient in a training device configured to assist with physical training that is configured to induce neurological signals in the hand or paw, and applying electrical stimulation to a portion of the cervical spinal cord of the subject.
Transcutaneous Stimulation of a Region of the Cervical Spine.
The location of the electrode and its stimulation parameters are important in defining motor response. Use of surface electrode(s), as described herein, facilitates selection or alteration of particular stimulation sites as well as the application of a wide variety of stimulation parameters. Additionally surface stimulation can be used to optimize location for an implantable electrode or electrode array for epidural stimulation.
In various embodiments, the methods described herein involve transcutaneous electrical stimulation of the cervical spine or a region of the cervical spine of the subject. Illustrative regions include, but are not limited to one or more regions straddling or spanning a region selected from the group consisting of C1-C1, C1-C2, C1-C3, C1-C4, C1-C7, C1-C6, C1-C7, C1-T1, C2-C2, C2-C3, C2-C4, C2-C5, C2-C6, C2-C7, C2-T1, C3-C3, C3-C4, C3-C5, C3-C6, C3-C7, C3-T1, C4-C4, C4-C5, C4-C6, C4-C7, C4-T1, C5-C5, C5-C6, C5-C7, C5-T1, C6-C6, C6-C7, C6-T1, C7-C7, and C7-T1.
In certain embodiments, the stimulation is stimulation at a frequency ranging from about 3 Hz, or from about 5 Hz, or from about 10 Hz to about 100 Hz, or to about 80 Hz, or to about 40 Hz, or from about 3 Hz or from about 5 Hz to about 80 Hz, or from about 5 Hz to about 30 Hz, or to about 40 Hz, or to about 50 Hz.
In certain embodiments, the transcutaneous stimulation is applied at an intensity ranging from about 10 mA to about 150 mA, or from about 20 mA to about 50 mA or to about 100 mA, or from about 20 mA or from about 30 mA, or from about 40 mA to about 50 mA, or to about 60 mA, or to about 70 mA or to about 80 mA.
In certain embodiments, the transcutaneous stimulation is at a frequency and amplitude sufficient to improve hand strength and/or fine hand control when applied in conjunction with a neuromodulatory agent (e.g., a monoaminergic agent). In certain embodiments the transcutaneous stimulation is at a frequency and amplitude sufficient to improve hand strength and/or fine hand control when applied in conjunction with an epidural stimulation of the cervical spinal cord or a region thereof. In certain embodiments the transcutaneous stimulation is at a frequency and amplitude sufficient to improve hand strength and/or fine hand control when applied in conjunction with a neuromodulatory agent (e.g., a monoaminergic agent) and epidural stimulation of the cervical spinal cord or a region thereof. In certain embodiments the transcutaneous stimulation is at a frequency and amplitude sufficient to improve hand strength and/or fine hand control when utilized without epidural stimulation and/or without a neuromodulatory agent.
Epidural Stimulation of a Region of the Cervical Spine
In various embodiments, the methods described herein involve epidural electrical stimulation of the cervical spine or a region of the cervical spine of the subject. Illustrative regions include, but are not limited to, one or more regions straddling or spanning a region selected from the group consisting of C1-C1, C1-C2, C1-C3, C1-C4, C1-C7, C1-C6, C1-C7, C1-T1, C2-C2, C2-C3, C2-C4, C2-C5, C2-C6, C2-C7, C2-T1, C3-C3, C3-C4, C3-C5, C3-C6, C3-C7, C3-T1, C4-C4, C4-C5, C4-C6, C4-C7, C4-T1, C5-C5, C5-C6, C5-C7, C5-T1, C6-C6, C6-C7, C6-T1, C7-C7, and C7-T1.
In certain embodiments, the epidural stimulation is at a frequency ranging from about 3 Hz, or from about 5 Hz, or from about 10 Hz to about 100 Hz, or to about 80 Hz, or to about 40 Hz, or from about 3 Hz or from about 5 Hz to about 80 Hz, or from about 5 Hz to about 30 Hz, or to about 40 Hz, or to about 50 Hz.
In certain embodiments, the epidural stimulation is at an amplitude ranging from 0.05 mA to about 30 mA, or from about 0.1 mA to about 20 mA, or from about 0.1 mA to about 15 mA or to about 10 mA.
In certain embodiments, the pulse width ranges from about 150 μs to about 600 μs, or from about 200 μs to about 500 μs, or from about 200 μs to about 450 μs.
In certain embodiments, the epidural stimulation is at a frequency and amplitude sufficient to improve hand strength and/or fine hand control. In certain embodiments the epidural stimulation is applied paraspinally over a cervical region identified above (e.g., over vertebrae spanning C2 to T1, over vertebrae spanning C5 to T1, etc.).
In certain embodiments, the epidural stimulation is applied via a permanently implanted electrode array (e.g., a typical density electrode array, a high density electrode array, etc.).
In certain embodiments, the epidural electrical stimulation is administered via a high density epidural stimulating array (e.g., as described in PCT Publication No: WO/2012/094346 (PCT/US2012/020112). In certain embodiments, the high density electrode arrays are prepared using microfabrication technology to place numerous electrodes in an array configuration on a flexible substrate. In some embodiments, epidural array fabrication methods for retinal stimulating arrays can be used in the methods described herein (see, e.g., Maynard (2001) Annu. Rev. Biomed. Eng., 3: 145-168; Weiland and Humayun (2005) IEEE Eng. Med. Biol. Mag., 24(5): 14-21, and U.S. Patent Publications 2006/0003090 and 2007/0142878). In various embodiments, the stimulating arrays comprise one or more biocompatible metals (e.g., gold, platinum, chromium, titanium, iridium, tungsten, and/or oxides and/or alloys thereof) disposed on a flexible material. Flexible materials can be selected from parylene A, parylene C, parylene AM, parylene F, parylene N, parylene D, other flexible substrate materials, or combinations thereof. Parylene has the lowest water permeability of available microfabrication polymers, is deposited in a uniquely conformal and uniform manner, has previously been classified by the FDA as a United States Pharmacopeia (USP) Class VI biocompatible material (enabling its use in chronic implants) (Wolgemuth, Medical Device and Diagnostic Industry, 22(8): 42-49 (2000)), and has flexibility characteristics (Young's modulus ˜4 GPa (Rodger and Tai (2005) IEEE Eng. Med. Biology, 24(5): 52-57)), lying in between those of PDMS (often considered too flexible) and most polyimides (often considered too stiff). Finally, the tear resistance and elongation at break of parylene are both large, minimizing damage to electrode arrays under surgical manipulation. The preparation and parylene microelectrode arrays suitable for use in the epidural stimulation methods described herein is described in PCT Publication No: WO/2012/100260 (PCT/US2012/022257).
The electrode array may be implanted using any of a number of methods (e.g., a laminectomy procedure) well known to those of skill in the art.
In various embodiments, the arrays are operably linked to control circuitry that permits selection of electrode(s) to activate/stimulate and/or that controls frequency, and/or pulse width, and/or amplitude of stimulation. In various embodiments, the electrode selection, frequency, amplitude, and pulse width are independently selectable, e.g., at different times, different electrodes can be selected. At any time, different electrodes can provide different stimulation frequencies and/or amplitudes. In various embodiments, different electrodes or all electrodes can be operated in a monopolar mode and/or a bipolar mode, using constant current or constant voltage delivery of the stimulation.
In certain embodiments, the electrodes can also be provided with implantable control circuitry and/or an implantable power source. In various embodiments, the implantable control circuitry can be programmed/reprogrammed by use of an external device (e.g., using a handheld device that communicates with the control circuitry through the skin). The programming can be repeated as often as necessary.
Any present or future developed stimulation system capable of providing an electrical signal to one or more regions of the cervical spinal cord may be used in accordance with the teachings provided herein. In various embodiments, the system may comprise an external pulse generator. In other embodiments the system may comprise an implantable pulse generator to produce a number of stimulation pulses that are sent to the a region in proximity to the cervical spinal cord by insulated leads coupled to the spinal cord by one or more electrodes and/or an electrode array. In certain embodiments the one or more electrodes or one or more electrodes comprising the electrode array may be attached to separate conductors included within a single lead. Any known or future developed lead useful for applying an electrical stimulation signal in proximity to a subject's spinal cord may be used. For example, the leads may be conventional percutaneous leads, such as PISCES® model 3487A sold by Medtronic, Inc. In some embodiments, it may be desirable to employ a paddle-type lead.
Any known or future developed external or implantable pulse generator may be used in accordance with the teachings provided herein. For example, one internal pulse generator may be an ITREL® II or Synergy pulse generator available from Medtronic, Inc, Advanced Neuromodulation Systems, Inc.'s GENESIS™ pulse generator, or Advanced Bionics Corporation's PRECISION™ pulse generator. One of skill in the art will recognize that the above-mentioned pulse generators may be advantageously modified to deliver therapy in accordance with the teachings provided herein.
In certain embodiments systems can employ a programmer coupled via a conductor to a radio frequency antenna. This system permits attending medical personnel to select the various pulse output options after implant using radio frequency communications. While, in certain embodiments, the system employs fully implanted elements, systems employing partially implanted elements may also be used in accordance with the teachings provided herein.
In one illustrative, but non-limiting system, a control module is operably coupled to a signal generation module and instructs the signal generation module regarding the signal to be generated. For example, at any given time or period of time, the control module may instruct the signal generation module to generate an electrical signal having a specified pulse width, frequency, intensity (current or voltage), etc. The control module may be preprogrammed prior to implantation or receive instructions from a programmer (or another source) through any known or future developed mechanism, such as telemetry. The control module may include or be operably coupled to memory to store instructions for controlling the signal generation module and may contain a processor for controlling which instructions to send to signal generation module and the timing of the instructions to be sent to signal generation module. In various embodiments, leads are operably coupled to signal generation module such that a stimulation pulse generated by signal generation module may be delivered via electrodes.
While in certain embodiments, two leads are utilized, it will be understood that any number of one or more leads may be employed. In addition, it will be understood that any number of one or more electrodes per lead may be employed. Stimulation pulses are applied to electrodes (which typically are cathodes) with respect to a return electrode (which typically is an anode) to induce a desired area of excitation of electrically excitable tissue in a region of the cervical spine. A return electrode such as a ground or other reference electrode can be located on same lead as a stimulation electrode. However, it will be understood that a return electrode may be located at nearly any location, whether in proximity to the stimulation electrode or at a more remote part of the body, such as at a metallic case of a pulse generator. It will be further understood that any number of one or more return electrodes may be employed. For example, there can be a respective return electrode for each cathode such that a distinct cathode/anode pair is formed for each cathode.
The epidural electrode stimulation systems described herein are intended to be illustrative and non-limiting. Using the teachings provided herein, alternative epidural stimulation systems and methods will be available to one of skill in the art.
Use of Neuromodulatory Agents.
In certain embodiments, the transcutaneous and/or epidural stimulation methods described herein are used in conjunction with various pharmacological agents, particularly pharmacological agents that have neuromodulatory activity (e.g., are monoamergic). In certain embodiments, the use of various serotonergic, and/or dopaminergic, and/or noradrenergic, and/or GABAergic, and/or glycinergic drugs is contemplated. These agents can be used in conjunction with epidural stimulation and/or transcutaneous stimulation and/or physical therapy as described above. This combined approach can help to put the spinal cord (e.g., the cervical spinal cord) in an optimal physiological state for controlling a range of hand movements.
In certain embodiments, the drugs are administered systemically, while in other embodiments, the drugs are administered locally, e.g., to particular regions of the spinal cord. Drugs that modulate the excitability of the spinal neuromotor networks include, but are not limited to combinations of noradrenergic, serotonergic, GABAergic, and glycinergic receptor agonists and antagonists.
Dosages of at least one drug or agent can be between about 0.001 mg/kg and about 10 mg/kg, between about 0.01 mg/kg and about 10 mg/kg, between about 0.01 mg/kg and about 1 mg/kg, between about 0.1 mg/kg and about 10 mg/kg, between about 5 mg/kg and about 10 mg/kg, between about 0.01 mg/kg and about 5 mg/kg, between about 0.001 mg/kg and about 5 mg/kg, or between about 0.05 mg/kg and about 10 mg/kg.
Drugs or agents can be delivery by injection (e.g., subcutaneously, intravenously, intramuscularly), orally, rectally, or inhaled.
Illustrative pharmacological agents include, but are not limited to, agonists and antagonists to one or more combinations of serotonergic: 5-HT1A, 5-HT2A, 5-HT3, and 5HT7 receptors; to noradrenergic alpha 1 and 2 receptors; and to dopaminergic D1 and D2 receptors (see, e.g., Table 1).
The foregoing methods are intended to be illustrative and non-limiting. Using the teachings provided herein, other methods involving transcutaneous electrical stimulation and/or epidural electrical stimulation and/or the use of neuromodulatory agents to improve motor control and/or strength of a hand or paw will be available to one of skill in the art.
The following examples are offered to illustrate, but not to limit the claimed invention.
The present Example demonstrates whether herein described neuromodulatory strategies can be used to improve fine motor control of the upper limbs, i.e., performance of motor tasks considered to be less “automatic” than posture and locomotion. Here we show that the injured human cervical spinal cord can be modulated using painless cutaneous electrical stimulation (pcEmc), monoaminergic agonist (fEmc) treatment, and/or eEmc to regain voluntary hand function. Mean hand strength increased greater than 300% after pcEmc plus fEmc (buspirone) treatment in 6 subjects with a chronic motor complete cervical injury. One subject that was implanted with a cervical epidural electrode array realized significantly improved hand strength and fine hand control in the presence of cervical eEmc. Thus, we now demonstrate that the cervical circuitry can be neuromodulated to improve volitional control of hand function in tetraplegic subjects with three novel interventions. The impact of these observations on individuals with upper limb paralysis could be dramatic functionally, psychologically, and economically.
Six subjects with chronic (18-36 months) spinal cord injury (SCI, traumatic cervical injury, ASIA B with no motor strength below the injury) were tested to determine if hand function can be improved by neuromodulating the cervical spinal cord. All subjects initially had minimal hand strength, a condition reflecting the majority of cervical SCI patients. Our experimental approach began with 6 weeks of baseline testing (Phase 1), followed by three 2-week treatment periods (Phases 2-4), and then by a period of approximately three months without any treatment at the end of which there was a final 2-week testing period (Phase 5). pcEmc at the C5 spinal segment (Phase 2) increased hand strength in 4/6 subjects compared to baseline Phase 1 (
These results show that the cervical spinal cord can be neuromodulated using two paradigms, i.e., electrically and pharmacologically. In some embodiments, the present methods are highly interactive and perhaps synergistic. Synergy and interactivity were observed in animal experiments. These data suggest that non-functional networks can become engaged and progressively improve motor performance. In some embodiments, further improvement in hand function after withdrawing pcEMC and fEMC can be a result of functional connections remaining active once they are established.
The improvements are unlikely to be due to natural recovery or from repeated practice as large cohort studies of SCI patients have demonstrated that the majority of functional improvements occur within 6 months of the injury and that minimal recovery of function is observed past the 12 month time-point. All of our subjects were 18 months beyond the initial injury when recruited. Furthermore, baseline motor function testing for 6 weeks prior to any therapeutic intervention revealed stable function (
Given the results above, we then asked whether the cervical spinal circuitry could be neuromodulated to improve hand function by stimulating via an epidural array implant (implanted in subject shown in
In the initial acute phase after implantation of a temporary trial array, the subject's ability to accurately follow a targeted force presented with a cursor moving in a sine wave pattern on a video screen was improved with eEmc (
After implantation of the permanent electrode array, we next performed a series of motor tests over the next 9 months comparing the effects of different stimulation parameters in facilitating maximum force and fine control. Maximal forces were generated at 10-20 Hz (
Accuracy in controlling force was performed approximately weekly over a period of eight months to identify the optimal stimulation parameters. Rapid oscillatory movements were performed at 20 Hz and 0.5 mA and at 10 and 30 Hz and 0.7 mA (
The present methods and systems provide that: 1) optimal stimulation parameters generating the highest forces differed from those generating the greatest accuracy at sub-maximal forces; 2) effects of stimulation intensity and frequency on maximum force production and accuracy are highly interdependent; 3) accuracy of force generation can be improved over time in the presence of eEmc; and 4) time needed to initiate a force following a command was prolonged, but could be improved with specific stimulation parameters. Each of these observations demonstrates the importance of matching the stimulation parameters with the task to be performed. In some embodiments, eEmc can yield improvement (e.g., meaningful) in upper extremity function in subjects with a cervical SCI.
Accuracy in controlling force was performed approximately weekly over a period of eight months to identify the optimal stimulation parameters. Rapid oscillatory movements were performed at 20 Hz and 0.5 mA and at 10 and 30 Hz and 0.7 mA (
The present methods and systems provide that: 1) optimal stimulation parameters generating the highest forces differed from those generating the greatest accuracy at sub-maximal forces; 2) effects of stimulation intensity and frequency on maximum force production and accuracy are highly interdependent; 3) accuracy of force generation can be improved over time in the presence of eEmc; and 4) time needed to initiate a force following a command was prolonged, but could be improved with specific stimulation parameters. Each of these observations demonstrates the importance of matching the stimulation parameters with the task to be performed. In some embodiments, eEmc can yield improvement (e.g., meaningful) in upper extremity function in subjects with a cervical SCI.
A dysfunctional interaction may exist between supraspinal and sensory networks given the externally imposed neuromodulation of the spinal circuitry and since neither the descending motor control nor the spinal circuitry had functioned in any significant interactive way since the injury. This interaction was explored between supraspinally derived descending volitional drive and sensory-derived input to the spinal networks and motor pools when the spinal circuitry was being neuromodulated with eEmc. Could supraspinal networks volitionally accommodate the ‘level of effort’ to the level of motor pool excitability imposed by eEmc? To address this question we asked the subject to generate a series of seven contractions at different levels of maximum efforts with and without stimulation (
PcEmc, fEmc, and eEmc interventions can enhance the level of excitability of pre-motor spinal circuitries that mediate hand function. The importance of these data is that they identify three novel interventional strategies having significant potential for high clinical impact in a relatively short timeframe on a function considered to be of highest priority among paralyzed patients. The impact of these results is significant from the following perspectives: 1) neuromodulation is not dependent on the physiological phenomenon of central pattern generation but also applies to fine neuromotor control of less “automatic” movements; 2) they raise the possibility that the neuromodulatory concept could apply to other neural networks and therefore could be applied to neuromotor disorders such as stroke and Parkinson disease; and 3) they demonstrate the potential of enhancing maximum neuromuscular force, as well as fine control of movements. The improved force potential was associated with improved performance in upper extremity tasks (ARAT). Importantly, even after more than a year of inactivity of the sensorimotor circuits, significant levels of activity-dependent plasticity persist.
Methods Summary
The University of California, Los Angeles Institutional Review Board approved all procedures. Subjects were enrolled based on the enrollment criteria of traumatic cervical injury, ASIA B, greater than 1 year from injury, and stable motor function as documented by sequential clinical exams. Baseline clinical scores (ARAT, ASIA) prior to study intervention were assessed (
Voluntary motor control data were assessed using a handgrip force measurement device. EMG data were collected via surface electrodes placed unilaterally on upper extremity muscles. Stimulation and data collection was obtained using the Konigsberg EMG system (Konigsberg, Pasadena, Calif.). Functional assessments by validated assessment tools were performed weekly during each study phase: American Spinal Injury Assessment (ASIA), and Action Research Arm Test (ARAT) (Carroll (1965) J, Chronic Dis., 18: 479-491). Two blinded examiners conducted the functional tests.
The transcutaneous stimulation device is non-invasive. Stimulation parameters ranged from 5-30 Hz and 20-100 mA, located at C5. From the midpoint of Phase 1 to the end of Phase 4 all subjects were informed that they would receive either a placebo or the monoaminergic agonist (7.5 mg buspirone twice daily for 2 weeks beginning the day before biweekly testing). All subjects received buspirone during Phase 3 and a placebo during Phases 1, 2, and 4. All subjects and testers were blinded.
A temporary trial with two 16-contact percutaneous epidural leads (Linear Lead, Boston Scientific, Valencia, Calif.) spanning C2 to T1 was conducted prior to permanent implantation in one subject. Indication for implantation was for treatment of pain. Stimulation intensity ranged between 0.1-10.0 mA, frequencies ranged between 5-60 Hz, and pulse width was at 210 or 450 ps. After 7 days, one Boston Scientific Artisan (Valencia, Calif.) 16-electrode epidural array and one Boston Scientific Precision Plus Spinal Cord Stimulator (Valencia, Calif.) were implanted encompassing C5 to T1. The effects of various combinations of stimulation parameters were assessed to obtain the best response for hand function. Stimulation intensity ranged between 0.13.0 mA, frequencies ranged between 5-60 Hz, and pulse width was at 210 or 450 ps.
Outcomes were averaged across all observations in a given phase/period for each subject. Group mean changes across subjects in grip strength, EMG amplitude, ARAT score and ASIA score from baseline over the 5 phases were compared using a non-parametric repeated measure analysis of variance model using re-sampling. A two sided p value of p<0.05 was considered significant. Means±standard error of the mean (SEM) are reported.
Methods.
Subject Profiles
The University of California, Los Angeles Institutional Review Board approved all procedures. Subjects were enrolled based on the enrollment criteria of traumatic cervical injury, ASIA B, greater than 1 year from injury, and stable motor function as documented by sequential clinical exams. The clinical profiles of the subjects upon enrollment into this study are as follows: Subject A was a 20 year old male who suffered a C6 SCI after a motor vehicle accident and was 36 months from initial injury; Subject B was a 18 year old male who suffered a C5 SCI after a diving accident and was 18 months from initial injury; Subject C was a 21 year old female who suffered a C2 SCI after a motor vehicle accident and was 45 months from initial injury; Subject D was a 20 year old male who suffered a C5 SCI sustained during football game and was 30 months from initial injury; Subject E was a 18 year old male who suffered a C5 SCI after a diving accident and was 24 months from initial injury; and Subject F was an 18 year old female with C6 SCI sustained after a fall from height and was 18 months from initial injury. Magnetic resonance imaging was obtained in all subjects to confirm location and description of injury (
Hand Testing
Voluntary motor control data were assessed using a handgrip force measurement device. Motor assessment was conducted on the arm that was most functional post-injury regardless of the pre-injury dominant side. Briefly, the device measures displacement against springs with a range in spring constants. Measurement of maximal voluntary contraction was conducted by asking the subject to contract his/her hand against the springs to maximally displace the handgrip. The contraction lasted for approximately 3-5 sec and was repeated twice. For hand oscillation/repeated contractions, the subject was asked to contract and release the hand as fast as possible above and below two lines on a computer screen that was preset at 12.5 and 37.5% of maximum voluntary contraction. The number of completed contraction-release sequences across the lines was determined. For hand control, the subject was asked to trace a sinusoidal wave (0.15 Hz) that appeared on the computer screen by squeezing the handgrip. The percentage of data points that fell inside a circular window at a sampling of 15 Hz was determined. The EMG data were collected via surface electrodes placed unilaterally on the biceps brachii (biceps), triceps brachii (triceps), brachioradialis (Brac), extensor digitorum (ED), flexor digitorum (FD), thenar, and hypothenar (H. Thenar) muscles. Stimulation and data collection was obtained using the Konigsberg EMG system (Konigsberg, Pasadena, Calif.). Functional assessments by validated assessment tools were performed weekly during each phase of study: American Spinal Injury Assessment (ASIA), and Action Research Arm Test (ARAT) (Carroll (1965) J, Chronic Dis., 18: 479-491).
ARAT was selected due its focus on arm motor ability and because it has been validated and applied in the SCI setting. Scoring was conducted by two experienced examiners who were not informed of the treatment phase (blinded). If discrepancy existed between the scores, the exam was repeated and a consensus reached.
Prior to initiation of the study, the stability of hand function and training effect of utilizing the handgrip was assessed over the course of 6 weeks during which the subjects were tested and trained with the handgrip twice/week. In all subjects assessed, there was no improvement in hand function during this baseline testing (
pcEMC and fEMC
The transcutaneous stimulation device is non-invasive. A surface stimulation cathode electrode was attached on the dorsal aspect of the neck (C5 area) and the grounding electrode was placed on the anterior superior iliac spine. Stimulation parameters ranged from 5-30 Hz and 20-100 mA. Varying combinations of these stimulation parameters were systematically assessed to obtain optimum facilitation of voluntary hand contraction by identification of the relative activation levels of the motor pools studied (data not shown). During each of the three treatment periods (Phases 2-4) a series of nine 3.5-sec maximum hand grip strength tests were performed per treatment session. In each session of Phase 2, three contractions were performed without pcEmc, followed by three in the presence of pcEmc (twice weekly at 30 Hz and 20-40 mA), followed by three without pcEmc. The same pcEmc protocol was followed during Phases 2-4. The duration of pcEmc during each testing session was approximately 15-30 min. The total number of maximum hand contractions was 9-36 and each session lasted 1 to 2 hours. During pcEMC, the subjects reported a non-painful, tingling sensation down the arms at the higher stimulation intensities at the site of stimulation with some associated tonic paraspinal muscle contractions at the neck.
From the midpoint of the Phase 1 to the end of Phase 4 all subjects were informed that they would receive either a placebo or the monoaminergic agonist buspirone. All subjects and testers were blinded as to which treatment was administered and were given buspirone (7.5 mg buspirone twice daily for 2 weeks beginning the day before biweekly testing) during Phase 3 and a placebo during Phases 1, 2, and 4.
eEMC
Planning for surgical placement of spinal cord epidural stimulator (eEmc) on subject E was initiated prior to study enrollment. The criteria for selection was based on Federal Drug Administration approved use for the treatment of pain and Dr. Lu and two other physicians confirmed the indication for implantation. A temporary trial with two 16-contact percutaneous epidural leads (Linear Lead, Boston Scientific, Valencia, Calif.) spanning C2 to T1 was conducted prior to permanent implantation. After implantation, testing was conducted over a 2-hour session to assess the efficacy for improving hand function. Stimulation amplitude ranged between 0.110.0 mA, frequencies ranged between 5-60 Hz, and pulse width was at 210 or 450 ps. Total time of stimulation was 30 min.
After 7 days of confirmed efficacy in the treatment of pain, one Boston Scientific Artisan (Valencia, Calif.) 16-electrode epidural array and one Boston Scientific Precision Plus Spinal Cord Stimulator (Valencia, Calif.) were implanted encompassing C5 to T1. The effects of various combinations of stimulation parameters were assessed to obtain the best response for hand function. A combined total of 60 testing sessions were conducted on Subject E over the course of 20 months (epidural implant occurred between testing session 21 and 22). Each testing session lasted up to 180 min. During each testing session, stimulation duration lasted between 30-120 min. Stimulation amplitude ranged between 0.1-3.0 mA, frequencies ranged between 5-60 Hz, and pulse width was at 210 or 450 ps. During low intensity eEMC, the subject reported a tingling sensation at the neck that migrated toward the arms and hands. At the optimal stimulation parameters, the subject reported the perception of increased hand strength and control similar to pre-injury ability.
Statistical Analysis
Outcome measures (grip strength force, EMG amplitude, ARAT score, ASIA score) were averaged across all observations in a given Phase for each subject. Using these values, group mean changes across subjects for each outcome measure from baseline over the 5 phases were compared using a non-parametric repeated measure analysis of variance model using re-sampling (bootstrap). The repeated measure mixed model takes into account the correlation across time on the same subjects. A two-sided p value of p<0.05 was considered significant. Standard error of the mean (SEM) are reported. Individual mean profiles and the corresponding within person SEM also are reported.
It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the appended claims. All publications, patents, and patent applications cited herein are hereby incorporated by reference in their entirety for all purposes.
This application is a continuation of U.S. Ser. No. 15/025,201, filed on Mar. 25, 2016, which is a 371 US National Phase of PCT/US2014/057886, filed on Sep. 26, 2014, which claims benefit of and priority to U.S. Ser. No. 61/883,694, filed on Sep. 27, 2013, all of which are incorporated herein by reference in their entirety for all purposes.
This invention was made with Government support under TR000124, awarded by the National Institutes of Health. The Government has certain rights in the invention.
| Number | Name | Date | Kind |
|---|---|---|---|
| 3543761 | Bradley | Dec 1970 | A |
| 3662758 | Glover | May 1972 | A |
| 3724467 | Avery et al. | Apr 1973 | A |
| 4044774 | Corbin et al. | Aug 1977 | A |
| 4102344 | Conway et al. | Jul 1978 | A |
| 4141365 | Fischell et al. | Feb 1979 | A |
| 4285347 | Hess | Aug 1981 | A |
| 4340063 | Maurer | Jul 1982 | A |
| 4379462 | Borkan et al. | Apr 1983 | A |
| 4414986 | Dickhudt et al. | Nov 1983 | A |
| 4538624 | Tarjan | Sep 1985 | A |
| 4549556 | Tajan et al. | Oct 1985 | A |
| 4559948 | Liss et al. | Dec 1985 | A |
| 4573481 | Bullara et al. | Mar 1986 | A |
| 4800898 | Hess et al. | Jan 1989 | A |
| 4934368 | Lynch | Jun 1990 | A |
| 4969452 | Petrofsky et al. | Nov 1990 | A |
| 5002053 | Garcia-Rill et al. | Mar 1991 | A |
| 5031618 | Mullett | Jul 1991 | A |
| 5066272 | Eaton et al. | Nov 1991 | A |
| 5081989 | Graupe et al. | Jan 1992 | A |
| 5121754 | Mullett | Jun 1992 | A |
| 5344439 | Otten | Sep 1994 | A |
| 5354320 | Schaldach et al. | Oct 1994 | A |
| 5374285 | Vaiani et al. | Dec 1994 | A |
| 5417719 | Hull et al. | May 1995 | A |
| 5476441 | Durfee et al. | Dec 1995 | A |
| 5562718 | Palermo | Oct 1996 | A |
| 5643330 | Holsheimer et al. | Jul 1997 | A |
| 5733322 | Starkebaum | Mar 1998 | A |
| 5983141 | Sluijter et al. | Nov 1999 | A |
| 6066163 | John | May 2000 | A |
| 6104957 | Alo et al. | Aug 2000 | A |
| 6122548 | Starkebaum et al. | Sep 2000 | A |
| 6308103 | Gielen | Oct 2001 | B1 |
| 6319241 | King et al. | Nov 2001 | B1 |
| 6463327 | Lurie et al. | Oct 2002 | B1 |
| 6470213 | Alley | Oct 2002 | B1 |
| 6500110 | Davey et al. | Dec 2002 | B1 |
| 6503231 | Prausnitz et al. | Jan 2003 | B1 |
| 6505074 | Boveja et al. | Jan 2003 | B2 |
| 6516227 | Meadows et al. | Feb 2003 | B1 |
| 6551849 | Kenney | Apr 2003 | B1 |
| 6587724 | Mann | Jul 2003 | B2 |
| 6662053 | Borkan | Dec 2003 | B2 |
| 6666831 | Edgerton et al. | Dec 2003 | B1 |
| 6685729 | Gonzalez | Feb 2004 | B2 |
| 6819956 | DiLorenzo | Nov 2004 | B2 |
| 6839594 | Cohen et al. | Jan 2005 | B2 |
| 6862479 | Whitehurst et al. | Mar 2005 | B1 |
| 6871099 | Whitehurst et al. | Mar 2005 | B1 |
| 6892098 | Ayal et al. | May 2005 | B2 |
| 6895280 | Meadows et al. | May 2005 | B2 |
| 6895283 | Erickson et al. | May 2005 | B2 |
| 6937891 | Leinders et al. | Aug 2005 | B2 |
| 6950706 | Rodriguez et al. | Sep 2005 | B2 |
| 6975907 | Zanakis et al. | Dec 2005 | B2 |
| 6988006 | King et al. | Jan 2006 | B2 |
| 6999820 | Jordan | Feb 2006 | B2 |
| 7020521 | Brewer et al. | Mar 2006 | B1 |
| 7024247 | Gliner et al. | Apr 2006 | B2 |
| 7035690 | Goetz | Apr 2006 | B2 |
| 7047084 | Erickson et al. | May 2006 | B2 |
| 7065408 | Herman et al. | Jun 2006 | B2 |
| 7096070 | Jenkins et al. | Aug 2006 | B1 |
| 7110820 | Tcheng et al. | Sep 2006 | B2 |
| 7127287 | Duncan et al. | Oct 2006 | B2 |
| 7127296 | Bradley | Oct 2006 | B2 |
| 7127297 | Law et al. | Oct 2006 | B2 |
| 7153242 | Goffer | Dec 2006 | B2 |
| 7184837 | Goetz | Feb 2007 | B2 |
| 7200443 | Faul | Apr 2007 | B2 |
| 7209787 | DiLorenzo | Apr 2007 | B2 |
| 7228179 | Campen et al. | Jun 2007 | B2 |
| 7239920 | Thacker et al. | Jul 2007 | B1 |
| 7251529 | Greenwood-Van Meerveld | Jul 2007 | B2 |
| 7252090 | Goetz | Aug 2007 | B2 |
| 7313440 | Miesel et al. | Dec 2007 | B2 |
| 7324853 | Ayal et al. | Jan 2008 | B2 |
| 7330760 | Heruth et al. | Feb 2008 | B2 |
| 7337005 | Kim et al. | Feb 2008 | B2 |
| 7337006 | Kim et al. | Feb 2008 | B2 |
| 7381192 | Brodard et al. | Jun 2008 | B2 |
| 7415309 | McIntyre | Aug 2008 | B2 |
| 7463928 | Lee et al. | Dec 2008 | B2 |
| 7467016 | Colborn | Dec 2008 | B2 |
| 7493170 | Segel et al. | Feb 2009 | B1 |
| 7496404 | Meadows et al. | Feb 2009 | B2 |
| 7502652 | Gaunt et al. | Mar 2009 | B2 |
| 7536226 | Williams et al. | May 2009 | B2 |
| 7544185 | Bengtsson | Jun 2009 | B2 |
| 7584000 | Erickson | Sep 2009 | B2 |
| 7590454 | Garabedian et al. | Sep 2009 | B2 |
| 7603178 | North et al. | Oct 2009 | B2 |
| 7628750 | Cohen et al. | Dec 2009 | B2 |
| 7660636 | Castel et al. | Feb 2010 | B2 |
| 7697995 | Cross et al. | Apr 2010 | B2 |
| 7729781 | Swoyer et al. | Jun 2010 | B2 |
| 7734340 | De Ridder | Jun 2010 | B2 |
| 7734351 | Testerman et al. | Jun 2010 | B2 |
| 7769463 | Katsnelson | Aug 2010 | B2 |
| 7797057 | Harris | Sep 2010 | B2 |
| 7801601 | Maschino et al. | Sep 2010 | B2 |
| 7813803 | Heruth et al. | Oct 2010 | B2 |
| 7813809 | Strother et al. | Oct 2010 | B2 |
| 7856264 | Firlik et al. | Dec 2010 | B2 |
| 7877146 | Rezai et al. | Jan 2011 | B2 |
| 7890182 | Parramon et al. | Feb 2011 | B2 |
| 7949395 | Kuzma | May 2011 | B2 |
| 7949403 | Palermo et al. | May 2011 | B2 |
| 7987000 | Moffitt et al. | Jul 2011 | B2 |
| 7991465 | Bartic et al. | Aug 2011 | B2 |
| 8019427 | Moffitt | Sep 2011 | B2 |
| 8050773 | Zhu | Nov 2011 | B2 |
| 8108052 | Boling | Jan 2012 | B2 |
| 8131358 | Moffitt et al. | Mar 2012 | B2 |
| 8155750 | Jaax et al. | Apr 2012 | B2 |
| 8170660 | Dacey, Jr. et al. | May 2012 | B2 |
| 8190262 | Gerber et al. | May 2012 | B2 |
| 8195304 | Strother et al. | Jun 2012 | B2 |
| 8214048 | Whitehurst et al. | Jul 2012 | B1 |
| 8229565 | Kim et al. | Jul 2012 | B2 |
| 8239038 | Wolf, II | Aug 2012 | B2 |
| 8260436 | Gerber et al. | Sep 2012 | B2 |
| 8271099 | Swanson | Sep 2012 | B1 |
| 8295936 | Wahlstrand et al. | Oct 2012 | B2 |
| 8311644 | Moffitt et al. | Nov 2012 | B2 |
| 8332029 | Glukhovsky et al. | Dec 2012 | B2 |
| 8346366 | Arle et al. | Jan 2013 | B2 |
| 8352036 | DiMarco et al. | Jan 2013 | B2 |
| 8355791 | Moffitt | Jan 2013 | B2 |
| 8355797 | Caparso et al. | Jan 2013 | B2 |
| 8364273 | De Ridder | Jan 2013 | B2 |
| 8369961 | Christman et al. | Feb 2013 | B2 |
| 8412345 | Moffitt | Apr 2013 | B2 |
| 8428728 | Sachs | Apr 2013 | B2 |
| 8442655 | Moffitt et al. | May 2013 | B2 |
| 8452406 | Arcot-Krishnamurthy et al. | May 2013 | B2 |
| 8588884 | Hegde et al. | Nov 2013 | B2 |
| 8700145 | Kilgard et al. | Apr 2014 | B2 |
| 8712546 | Kim et al. | Apr 2014 | B2 |
| 8750957 | Tang et al. | Jun 2014 | B2 |
| 8805542 | Tai et al. | Aug 2014 | B2 |
| 9072891 | Rao | Jul 2015 | B1 |
| 9101769 | Edgerton et al. | Aug 2015 | B2 |
| 9205259 | Kim et al. | Dec 2015 | B2 |
| 9205260 | Kim et al. | Dec 2015 | B2 |
| 9205261 | Kim et al. | Dec 2015 | B2 |
| 9272143 | Libbus et al. | Mar 2016 | B2 |
| 9283391 | Ahmed | Mar 2016 | B2 |
| 9393409 | Edgerton et al. | Jul 2016 | B2 |
| 9409023 | Burdick et al. | Aug 2016 | B2 |
| 9415218 | Edgerton et al. | Aug 2016 | B2 |
| 9610442 | Yoo et al. | Apr 2017 | B2 |
| 9993642 | Gerasimenko et al. | Jun 2018 | B2 |
| 10137299 | Lu | Nov 2018 | B2 |
| 10751533 | Edgerton et al. | Aug 2020 | B2 |
| 10773074 | Liu et al. | Sep 2020 | B2 |
| 10806927 | Edgerton et al. | Oct 2020 | B2 |
| 20020055779 | Andrews | May 2002 | A1 |
| 20020111661 | Cross et al. | Aug 2002 | A1 |
| 20020115945 | Herman et al. | Aug 2002 | A1 |
| 20020193843 | Hill et al. | Dec 2002 | A1 |
| 20030032992 | Thacker et al. | Feb 2003 | A1 |
| 20030078633 | Firlik et al. | Apr 2003 | A1 |
| 20030100933 | Ayal et al. | May 2003 | A1 |
| 20030158583 | Burnett et al. | Aug 2003 | A1 |
| 20030220679 | Han | Nov 2003 | A1 |
| 20030233137 | Paul, Jr. | Dec 2003 | A1 |
| 20040039425 | Greenwood-Van Meerveld | Feb 2004 | A1 |
| 20040044380 | Bruninga et al. | Mar 2004 | A1 |
| 20040111118 | Hill et al. | Jun 2004 | A1 |
| 20040111126 | Tanagho et al. | Jun 2004 | A1 |
| 20040122483 | Nathan et al. | Jun 2004 | A1 |
| 20040127954 | McDonald et al. | Jul 2004 | A1 |
| 20040133248 | Frei et al. | Jul 2004 | A1 |
| 20040138518 | Rise et al. | Jul 2004 | A1 |
| 20050004622 | Cullen et al. | Jan 2005 | A1 |
| 20050070982 | Heruth et al. | Mar 2005 | A1 |
| 20050075669 | King | Apr 2005 | A1 |
| 20050075678 | Faul | Apr 2005 | A1 |
| 20050102007 | Ayal et al. | May 2005 | A1 |
| 20050113882 | Cameron et al. | May 2005 | A1 |
| 20050119713 | Whitehurst et al. | Jun 2005 | A1 |
| 20050125045 | Brighton et al. | Jun 2005 | A1 |
| 20050209655 | Bradley et al. | Sep 2005 | A1 |
| 20050246004 | Cameron et al. | Nov 2005 | A1 |
| 20050278000 | Strother et al. | Dec 2005 | A1 |
| 20060003090 | Rodger et al. | Jan 2006 | A1 |
| 20060041295 | Osypka | Feb 2006 | A1 |
| 20060089696 | Olsen et al. | Apr 2006 | A1 |
| 20060100671 | Ridder | May 2006 | A1 |
| 20060111754 | Rezai et al. | May 2006 | A1 |
| 20060122678 | Olsen et al. | Jun 2006 | A1 |
| 20060142816 | Fruitman et al. | Jun 2006 | A1 |
| 20060142822 | Tulgar | Jun 2006 | A1 |
| 20060149333 | Tanagho et al. | Jul 2006 | A1 |
| 20060149337 | John | Jul 2006 | A1 |
| 20060239482 | Hatoum | Oct 2006 | A1 |
| 20060282127 | Zealear | Dec 2006 | A1 |
| 20070016097 | Farquhar et al. | Jan 2007 | A1 |
| 20070016266 | Paul, Jr. | Jan 2007 | A1 |
| 20070049814 | Muccio | Mar 2007 | A1 |
| 20070055337 | Tanrisever | Mar 2007 | A1 |
| 20070060954 | Cameron et al. | Mar 2007 | A1 |
| 20070060980 | Strother et al. | Mar 2007 | A1 |
| 20070073357 | Rooney et al. | Mar 2007 | A1 |
| 20070083240 | Peterson et al. | Apr 2007 | A1 |
| 20070156179 | Karashurov | Jul 2007 | A1 |
| 20070168008 | Olsen | Jul 2007 | A1 |
| 20070179534 | Firlik et al. | Aug 2007 | A1 |
| 20070191709 | Swanson | Aug 2007 | A1 |
| 20070208381 | Hill et al. | Sep 2007 | A1 |
| 20070233204 | Lima et al. | Oct 2007 | A1 |
| 20070255372 | Metzler et al. | Nov 2007 | A1 |
| 20070265679 | Bradley et al. | Nov 2007 | A1 |
| 20070265691 | Swanson | Nov 2007 | A1 |
| 20070276449 | Gunter et al. | Nov 2007 | A1 |
| 20070276450 | Meadows et al. | Nov 2007 | A1 |
| 20080004674 | King et al. | Jan 2008 | A1 |
| 20080021513 | Thacker et al. | Jan 2008 | A1 |
| 20080046049 | Skubitz et al. | Feb 2008 | A1 |
| 20080051851 | Lin | Feb 2008 | A1 |
| 20080071325 | Bradley | Mar 2008 | A1 |
| 20080103579 | Gerber | May 2008 | A1 |
| 20080140152 | Imran et al. | Jun 2008 | A1 |
| 20080140169 | Imran | Jun 2008 | A1 |
| 20080147143 | Popovic et al. | Jun 2008 | A1 |
| 20080154329 | Pyles et al. | Jun 2008 | A1 |
| 20080183224 | Barolat | Jul 2008 | A1 |
| 20080200749 | Zheng et al. | Aug 2008 | A1 |
| 20080202940 | Jiang et al. | Aug 2008 | A1 |
| 20080207985 | Farone | Aug 2008 | A1 |
| 20080215113 | Pawlowicz | Sep 2008 | A1 |
| 20080221653 | Agrawal et al. | Sep 2008 | A1 |
| 20080228241 | Sachs | Sep 2008 | A1 |
| 20080228250 | Mironer | Sep 2008 | A1 |
| 20080234791 | Arle et al. | Sep 2008 | A1 |
| 20080279896 | Heinen et al. | Nov 2008 | A1 |
| 20090012436 | Lanfermann et al. | Jan 2009 | A1 |
| 20090093854 | Leung et al. | Apr 2009 | A1 |
| 20090112281 | Miyazawa et al. | Apr 2009 | A1 |
| 20090118365 | Benson, III et al. | May 2009 | A1 |
| 20090157141 | Chiao et al. | Jun 2009 | A1 |
| 20090198305 | Naroditsky et al. | Aug 2009 | A1 |
| 20090204173 | Fang et al. | Aug 2009 | A1 |
| 20090270960 | Zhao et al. | Oct 2009 | A1 |
| 20090281599 | Thacker et al. | Nov 2009 | A1 |
| 20090299166 | Nishida et al. | Dec 2009 | A1 |
| 20090299167 | Seymour | Dec 2009 | A1 |
| 20090306491 | Haggers | Dec 2009 | A1 |
| 20100004715 | Fahey | Jan 2010 | A1 |
| 20100023103 | Elborno | Jan 2010 | A1 |
| 20100042193 | Slavin | Feb 2010 | A1 |
| 20100070007 | Parker et al. | Mar 2010 | A1 |
| 20100114239 | McDonald et al. | May 2010 | A1 |
| 20100125313 | Lee et al. | May 2010 | A1 |
| 20100137938 | Kishawi et al. | Jun 2010 | A1 |
| 20100145428 | Cameron et al. | Jun 2010 | A1 |
| 20100152811 | Flaherty | Jun 2010 | A1 |
| 20100185253 | Dimarco et al. | Jul 2010 | A1 |
| 20100198298 | Glukhovsky et al. | Aug 2010 | A1 |
| 20100217355 | Tass et al. | Aug 2010 | A1 |
| 20100228310 | Shuros et al. | Sep 2010 | A1 |
| 20100241191 | Testerman et al. | Sep 2010 | A1 |
| 20100268299 | Farone | Oct 2010 | A1 |
| 20100274312 | Alataris et al. | Oct 2010 | A1 |
| 20100305660 | Hegi et al. | Dec 2010 | A1 |
| 20100318168 | Bighetti | Dec 2010 | A1 |
| 20100331925 | Peterson | Dec 2010 | A1 |
| 20110029040 | Walker et al. | Feb 2011 | A1 |
| 20110040349 | Graupe | Feb 2011 | A1 |
| 20110054567 | Lane et al. | Mar 2011 | A1 |
| 20110054568 | Lane et al. | Mar 2011 | A1 |
| 20110054579 | Kumar et al. | Mar 2011 | A1 |
| 20110125203 | Simon et al. | May 2011 | A1 |
| 20110130804 | Lin et al. | Jun 2011 | A1 |
| 20110152967 | Simon et al. | Jun 2011 | A1 |
| 20110160810 | Griffith | Jun 2011 | A1 |
| 20110166546 | Jaax et al. | Jul 2011 | A1 |
| 20110184488 | De Ridder | Jul 2011 | A1 |
| 20110184489 | Nicolelis et al. | Jul 2011 | A1 |
| 20110218594 | Doran et al. | Sep 2011 | A1 |
| 20110224665 | Crosby et al. | Sep 2011 | A1 |
| 20110224752 | Rolston et al. | Sep 2011 | A1 |
| 20110224753 | Palermo et al. | Sep 2011 | A1 |
| 20110224757 | Zdeblick et al. | Sep 2011 | A1 |
| 20110230701 | Simon et al. | Sep 2011 | A1 |
| 20110230702 | Honour | Sep 2011 | A1 |
| 20110245734 | Wagner et al. | Oct 2011 | A1 |
| 20110276107 | Simon et al. | Nov 2011 | A1 |
| 20110288609 | Tehrani et al. | Nov 2011 | A1 |
| 20110295100 | Rolston et al. | Dec 2011 | A1 |
| 20120006793 | Swanson | Jan 2012 | A1 |
| 20120029528 | Macdonald et al. | Feb 2012 | A1 |
| 20120035684 | Thompson et al. | Feb 2012 | A1 |
| 20120101326 | Simon et al. | Apr 2012 | A1 |
| 20120109251 | Lebedev et al. | May 2012 | A1 |
| 20120109295 | Fan | May 2012 | A1 |
| 20120123293 | Shah et al. | May 2012 | A1 |
| 20120126392 | Kalvesten et al. | May 2012 | A1 |
| 20120165899 | Gliner | Jun 2012 | A1 |
| 20120172946 | Altaris et al. | Jul 2012 | A1 |
| 20120179222 | Jaax et al. | Jul 2012 | A1 |
| 20120185020 | Simon et al. | Jul 2012 | A1 |
| 20120197338 | Su et al. | Aug 2012 | A1 |
| 20120221073 | Southwell et al. | Aug 2012 | A1 |
| 20120232615 | Barolat et al. | Sep 2012 | A1 |
| 20120252874 | Feinstein et al. | Oct 2012 | A1 |
| 20120259380 | Pyles | Oct 2012 | A1 |
| 20120277824 | Li | Nov 2012 | A1 |
| 20120277834 | Mercanzini et al. | Nov 2012 | A1 |
| 20120283697 | Kim et al. | Nov 2012 | A1 |
| 20120283797 | De Ridder | Nov 2012 | A1 |
| 20120302821 | Burnett | Nov 2012 | A1 |
| 20120310305 | Kaula et al. | Dec 2012 | A1 |
| 20120310315 | Savage et al. | Dec 2012 | A1 |
| 20120330391 | Bradley et al. | Dec 2012 | A1 |
| 20130012853 | Brown | Jan 2013 | A1 |
| 20130013041 | Glukhovsky et al. | Jan 2013 | A1 |
| 20130030319 | Hettrick et al. | Jan 2013 | A1 |
| 20130030501 | Feler et al. | Jan 2013 | A1 |
| 20130053734 | Barriskill et al. | Feb 2013 | A1 |
| 20130053922 | Ahmed et al. | Feb 2013 | A1 |
| 20130066392 | Simon et al. | Mar 2013 | A1 |
| 20130085317 | Feinstein | Apr 2013 | A1 |
| 20130110196 | Alataris et al. | May 2013 | A1 |
| 20130123568 | Hamilton et al. | May 2013 | A1 |
| 20130123659 | Bartol et al. | May 2013 | A1 |
| 20130165991 | Kim et al. | Jun 2013 | A1 |
| 20130197408 | Goldfarb et al. | Aug 2013 | A1 |
| 20130204324 | Thacker et al. | Aug 2013 | A1 |
| 20130253299 | Weber et al. | Sep 2013 | A1 |
| 20130253611 | Lee et al. | Sep 2013 | A1 |
| 20130268016 | Xi et al. | Oct 2013 | A1 |
| 20130268021 | Moffitt | Oct 2013 | A1 |
| 20130281890 | Mishelevich | Oct 2013 | A1 |
| 20130289446 | Stone et al. | Oct 2013 | A1 |
| 20130303873 | Voros et al. | Nov 2013 | A1 |
| 20130304159 | Simon et al. | Nov 2013 | A1 |
| 20130310911 | Tai et al. | Nov 2013 | A1 |
| 20140031893 | Walker et al. | Jan 2014 | A1 |
| 20140046407 | Ben-Ezra et al. | Feb 2014 | A1 |
| 20140058490 | DiMarco | Feb 2014 | A1 |
| 20140066950 | Macdonald et al. | Mar 2014 | A1 |
| 20140067007 | Drees et al. | Mar 2014 | A1 |
| 20140067354 | Kaula et al. | Mar 2014 | A1 |
| 20140081071 | Simon et al. | Mar 2014 | A1 |
| 20140100633 | Mann et al. | Apr 2014 | A1 |
| 20140107397 | Simon et al. | Apr 2014 | A1 |
| 20140107398 | Simon et al. | Apr 2014 | A1 |
| 20140114374 | Rooney et al. | Apr 2014 | A1 |
| 20140163640 | Edgerton et al. | Jun 2014 | A1 |
| 20140180361 | Burdick et al. | Jun 2014 | A1 |
| 20140213842 | Simon et al. | Jul 2014 | A1 |
| 20140236257 | Parker et al. | Aug 2014 | A1 |
| 20140296752 | Edgerton et al. | Oct 2014 | A1 |
| 20140303901 | Sadeh | Oct 2014 | A1 |
| 20140316484 | Edgerton et al. | Oct 2014 | A1 |
| 20140316503 | Tai et al. | Oct 2014 | A1 |
| 20140324118 | Simon et al. | Oct 2014 | A1 |
| 20140330067 | Jordan | Nov 2014 | A1 |
| 20140330335 | Errico et al. | Nov 2014 | A1 |
| 20140336722 | Rocon De Lima et al. | Nov 2014 | A1 |
| 20140357936 | Simon et al. | Dec 2014 | A1 |
| 20150005840 | Pal et al. | Jan 2015 | A1 |
| 20150065559 | Feinstein et al. | Mar 2015 | A1 |
| 20150165226 | Simon et al. | Jun 2015 | A1 |
| 20150182784 | Barriskill et al. | Jul 2015 | A1 |
| 20150190634 | Rezai et al. | Jul 2015 | A1 |
| 20150231396 | Burdick et al. | Aug 2015 | A1 |
| 20150265830 | Simon et al. | Sep 2015 | A1 |
| 20160030737 | Gerasimenko | Feb 2016 | A1 |
| 20160030748 | Edgerton et al. | Feb 2016 | A1 |
| 20160045727 | Rezai et al. | Feb 2016 | A1 |
| 20160045731 | Simon et al. | Feb 2016 | A1 |
| 20160074663 | De Ridder | Mar 2016 | A1 |
| 20160121109 | Edgerton et al. | May 2016 | A1 |
| 20160121114 | Simon et al. | May 2016 | A1 |
| 20160121116 | Simon et al. | May 2016 | A1 |
| 20160175586 | Edgerton et al. | Jun 2016 | A1 |
| 20160220813 | Edgerton et al. | Aug 2016 | A1 |
| 20160235977 | Lu et al. | Aug 2016 | A1 |
| 20160271413 | Vallejo et al. | Sep 2016 | A1 |
| 20160339239 | Yoo et al. | Nov 2016 | A1 |
| 20170007831 | Edgerton et al. | Jan 2017 | A1 |
| 20170157389 | Tai et al. | Jun 2017 | A1 |
| 20170161454 | Grill et al. | Jun 2017 | A1 |
| 20170165497 | Lu | Jun 2017 | A1 |
| 20170246450 | Liu et al. | Aug 2017 | A1 |
| 20170246452 | Liu et al. | Aug 2017 | A1 |
| 20170274209 | Edgerton et al. | Sep 2017 | A1 |
| 20170296837 | Jin | Oct 2017 | A1 |
| 20180185642 | Lu | Jul 2018 | A1 |
| 20180256906 | Pivonka et al. | Sep 2018 | A1 |
| 20180280693 | Edgerton et al. | Oct 2018 | A1 |
| 20180361146 | Gerasimenko et al. | Dec 2018 | A1 |
| 20190022371 | Chang et al. | Jan 2019 | A1 |
| 20190381313 | Lu | Dec 2019 | A1 |
| 20200155865 | Lu | May 2020 | A1 |
| Number | Date | Country |
|---|---|---|
| 2012204526 | Jul 2013 | AU |
| 2 823 592 | Jul 2012 | CA |
| 2 856 202 | May 2013 | CA |
| 2 864 473 | May 2013 | CA |
| 101227940 | Jul 2008 | CN |
| 103263727 | Aug 2013 | CN |
| 104307098 | Jan 2015 | CN |
| 2661307 | Nov 2013 | EP |
| 2968940 | Jan 2016 | EP |
| H03-26620 | Feb 1991 | JP |
| 2007-526798 | Sep 2007 | JP |
| 2008-543429 | Dec 2008 | JP |
| 2130326 | May 1999 | RU |
| 2141851 | Nov 1999 | RU |
| 2160127 | Dec 2000 | RU |
| 2178319 | Jan 2002 | RU |
| 2192897 | Nov 2002 | RU |
| 2001102533 | Nov 2002 | RU |
| 2226114 | Mar 2004 | RU |
| 2258496 | Aug 2005 | RU |
| 2361631 | Jul 2009 | RU |
| 2368401 | Sep 2009 | RU |
| 2387467 | Apr 2010 | RU |
| 2396995 | Aug 2010 | RU |
| 2397788 | Aug 2010 | RU |
| 2445990 | Mar 2012 | RU |
| 2471518 | Jan 2013 | RU |
| 2475283 | Feb 2013 | RU |
| WO 97047357 | Dec 1997 | WO |
| WO 03026735 | Apr 2003 | WO |
| WO 03092795 | Nov 2003 | WO |
| WO 2004087116 | Oct 2004 | WO |
| WO 2005051306 | Jun 2005 | WO |
| WO 2005065768 | Jul 2005 | WO |
| WO 2005087307 | Sep 2005 | WO |
| WO 2006138069 | Dec 2006 | WO |
| WO 2007007058 | Jan 2007 | WO |
| WO 2007012114 | Feb 2007 | WO |
| WO 2007107831 | Sep 2007 | WO |
| WO 2008109862 | Sep 2008 | WO |
| WO 2008121891 | Oct 2008 | WO |
| WO 2009042217 | Apr 2009 | WO |
| WO 2009111142 | Sep 2009 | WO |
| WO 2010055421 | May 2010 | WO |
| WO 2010114998 | Oct 2010 | WO |
| WO 2010124128 | Oct 2010 | WO |
| WO 2012094346 | Jul 2012 | WO |
| WO 2012100260 | Jul 2012 | WO |
| WO 2012129574 | Sep 2012 | WO |
| WO 2013071307 | May 2013 | WO |
| WO 2013071309 | May 2013 | WO |
| WO 2013188965 | Dec 2013 | WO |
| WO 2014144785 | Sep 2014 | WO |
| WO 2015048563 | Apr 2015 | WO |
| WO 2016029159 | Feb 2016 | WO |
| WO 2016033369 | Mar 2016 | WO |
| WO 2016033372 | Mar 2016 | WO |
| WO 2017011410 | Jan 2017 | WO |
| WO 2017024276 | Feb 2017 | WO |
| WO 2017035512 | Mar 2017 | WO |
| WO 2017044904 | Mar 2017 | WO |
| WO 2018106843 | Jun 2018 | WO |
| WO 2018140531 | Aug 2018 | WO |
| WO 2018217791 | Nov 2018 | WO |
| WO 2020041502 | Feb 2020 | WO |
| WO 2020041633 | Feb 2020 | WO |
| WO 2020236946 | Nov 2020 | WO |
| Entry |
|---|
| U.S. Office Action dated Apr. 8, 2015 issued in U.S. Appl. No. 14/355,812. |
| U.S. Final Office Action dated Sep. 21, 2015 issued in U.S. Appl. No. 14/355,812. |
| U.S. Notice of Allowance dated Apr. 13, 2016 issued in U.S. Appl. No. 14/355,812. |
| U.S. Office Action dated Oct. 18, 2016 issued in U.S. Appl. No. 15/208,529. |
| U.S. Final Office Action dated Jul. 13, 2017 issued in U.S. Appl. No. 15/208,529. |
| U.S. Office Action dated Jul. 27, 2018 issued in U.S. Appl. No. 15/208,529. |
| U.S. Office Action dated Oct. 3, 2017 issued in U.S. Appl. No. 15/025,201. |
| U.S. Notice of Allowance dated Aug. 1, 2018 issued in U.S. Appl. No. 15/025,201. |
| U.S. Office Action dated Jul. 13, 2016 issued in U.S. Appl. No. 14/775,618. |
| U.S. Final Office Action dated Apr. 25, 2017 issued in U.S. Appl. No. 14/775,618. |
| U.S. Notice of Allowance dated Jan. 18, 2018 issued in U.S. Appl. No. 14/775,618. |
| PCT International Search Report dated Jul. 30, 2012 issued in PCT/US2012/020112. |
| PCT International Preliminary Report on Patentability and Written Opinion dated Jul. 10, 2013 issued in PCT/US2012/020112. |
| PCT International Search Report and Written Opinion dated Mar. 19, 2013 issued in PCT/US2012/064878. |
| PCT International Preliminary Report on Patentability dated May 22, 2014 issued in PCT/US2012/064878. |
| Australian Patent Examination Report No. 1 dated Jul. 11, 2016 issued in AU 2012334926. |
| Canadian Office Action dated Aug. 31, 2018 issued in CA 2,864,473. |
| European Communication pursuant to Rule 114(2) EPC regarding observations by a third party dated Mar. 27, 2015 issued in EP 12 847 885.6. |
| European Extended Search Report dated May 6, 2015 issued in EP 12 847 885.6. |
| European Office Action dated Apr. 15, 2016 issued in EP 12 847 885.6. |
| European Reply to Communication of Apr. 15, 2016 dated Oct. 24, 2016 in EP 12 847 885.6. |
| European Second Office Action dated Feb. 16, 2017 issued in EP 12 847 885.6. |
| PCT Declaration of Non-Establishment of International Search Report and Written Opinion dated Dec. 24, 2014 issued in PCT/US2014/057886. |
| PCT International Preliminary Report on Patentability and Written Opinion dated Apr. 7, 2016 issued in PCT/US2014/057886. |
| Australian Examination report No. 1 dated Jan. 11, 2019 issued in AU 2014324660. |
| European Extended Search Report dated May 10, 2017 issued in EP 14849355.4. |
| European Office Action dated Jul. 20, 2018 issued in EP 14849355.4. |
| PCT International Search Report and Written Opinion dated Aug. 6, 2014 issued in PCT/US2014/029340. |
| PCT International Preliminary Report on Patentability dated Sep. 24, 2015 issued in PCT/US2014/029340. |
| Australian Patent Examination Report No. 1 dated May 11, 2018 issued in AU 2014228794. |
| European Extended Search Report dated Nov. 8, 2016 issued in EP 14 76 5477.6. |
| European Office Action dated Nov. 14, 2018 issued in EP 14 76 5477.6. |
| PCT International Search Report and Written Opinion dated Dec. 5, 2016 issued in PCT/US2016/045898. |
| PCT International Preliminary Report on Patentability and Written Opinion dated Feb. 15, 2018 issued in PCT/US2016/045898. |
| European Extended Search Report dated Dec. 13, 2018 issued in EP 16833973.7. |
| PCT International Search Report and Written Opinion dated Dec. 8, 2015 issued in PCT/US2015/047268. |
| PCT International Preliminary Report on Patentability and Written Opinion dated Feb. 28, 2017 issued in PCT/US2015/047268. |
| European Extended Search Report dated Mar. 1, 2018 issued in EP 15836927.2. |
| PCT International Search Report and Written Opinion dated Dec. 3, 2015 issued in PCT/US2015/047272. |
| PCT International Preliminary Report on Patentability and Written Opinion dated Feb. 28, 2017 issued in PCT/US2015/047272. |
| PCT Declaration of Non-Establishment of International Search Report and Written Opinion dated Dec. 1, 2015 issued in PCT/US2015/046378. |
| PCT International Preliminary Report on Patentability and Written Opinion dated Feb. 21, 2017 issued in PCT/US2015/046378. |
| European Extended Search Report dated Apr. 4, 2018 issued in EP 15834593.4. |
| PCT International Search Report and Written Opinion dated Sep. 12, 2016 issued in PCT/US2016/041802. |
| PCT International Preliminary Report on Patentability and Written Opinion dated Jan. 25, 2018 issued in PCT/US2016/041802. |
| PCT International Search Report and Written Opinion dated Dec. 5, 2016 issued in PCT/US2016/049129. |
| PCT International Preliminary Report on Patentability and Written Opinion dated Mar. 8, 2018 issued in PCT/US2016/049129. |
| PCT International Search Report and Written Opinion dated Mar. 12, 2018 issued in PCT/US2018/015098. |
| PCT International Search Report and Written Opinion dated Aug. 31, 2018 issued in PCT/US2018/033942. |
| PCT International Search Report dated Mar. 19, 2013 issued in PCT/US2012/064874. |
| PCT International Search Report dated Mar. 19, 2013 issued in PCT/US2012/064878. |
| PCT International Search Report dated Sep. 3, 2012 issued in PCT/US2012/022257. |
| PCT International Search Report dated Oct. 31, 2012 issued in PCT/US2012/030624. |
| Angeli et al. (2014) “Altering spinal cord excitability enables voluntary movements after chronic complete paralysis in humans” Brain 137: 1394-1409. |
| Courtine, Grégoire et al. (2007) “Modulation of multisegmental monosynaptic responses in a variety of leg muscles during walking and running in humans,” J Physiol. 582.3:1125-1139. |
| Danner S.M., Hofstoetter U.S., Ladenbauer J., Rattay F., and Minassian K. (Mar. 2011) “Can the human lumbar posterior columns be stimulated by transcutaneous spinal cord stimulation? A modeling study” Europe PMC Funders Author Manuscripts, Artif Organs 35(3):257-262, 12 pp. |
| DeSantana et al. (Dec. 2008) “Effectiveness of Transcutaneous Electrical Nerve Stimulation for Treatment of Hyperalgesia and Pain,” Curr Rheumatol Rep. 10(6):492-499, 12 pp. |
| Dubinsky, Richard M. and Miyasaki, Janis, “Assessment: Efficacy of transcutaneous electric nerve stimulation in the treatment of pain in neurologic disorders (an evidence-based review),” Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology, (2010) Neurology, 74:173-176. |
| Fong et al. (2009) “Recovery of control of posture and locomotion after a spinal cord injury: solutions staring us in the face,” Progress in Brain Research, Elsevier Amsterdam, NL,175:393-418. |
| Ganley et al., (2005) “Epidural Spinal Cord Stimulation Improves Locomoter Performance in Low ASIA C, Wheelchair-Dependent, Spinal Cord-Injured Individuals: Insights from Metabolic Response,” Top. Spinal Cord lnj. Rehabil;11(2):50-63. |
| Gerasimenko Y., Gorodnichev R., Machueva E., Pivovarova E., Semyenov D., Savochin A., Roy R.R., and Edgerton V.R., (Mar. 10, 2010) “Novel and Direct Access to the Human Locomotor Spinal Circuitry,” J Neurosci. 30(10):3700-3708, PMC2847395. |
| Gerasimenko Y.P., Ichiyama R.M., Lavrov I.A., Courtine G., Cai L., Zhong H., Roy R.R., and Edgerton V.R. (2007) “Epidural Spinal Cord Stimulation Plus Quipazine Administration Enable Stepping in Complete Spinal Adult Rats,” J Neurophysiol. 98:2525-2536. |
| Harkema et al. (2011) “Effect of Epidural stimulation of the lumbosacral spinal cord on voluntary movement, standing, and assisted stepping after motor complete paraplegia: a case study” Lancet 377(9781): 1938-1947; NIH Public Access Author Manuscript 17 pages [doi:10.1016/S0140-6736(11)60547-3]. |
| Herman R., He J., D'Luzansky S., Willis W., Dilli S., (2002) “Spinal cord stimulation facilitates functional walking in a chronic, incomplete spinal cord injured,” Spinal Cord. 40:65-68. |
| Hofstoetter, U.S. et al. (Aug. 2008) “Modification of Reflex Responses to Lumbar Posterior Root Stimulation by Motor Tasks in Healthy Subjects,” Artif Organs, 32(8):644-648. |
| Ichiyama et al. (2005) “Hindlimb stepping movements in complete spinal rats induced by epidural spinal cord stimulation” Neuroscience Letters, 383:339-344. |
| Kitano K., Koceja D.M. (2009) “Spinal reflex in human lower leg muscles evoked by transcutaneous spinal cord stimulation,” J Neurosci Methods. 180:111-115. |
| Minasian et al. (2010) “Transcutaneous stimulation of the human lumbar spinal cord: Facilitating locomotor output in spinal cord injury,” Conf. Proceedings Soc. for Neurosci., Abstract No. 286.19, 1 page. |
| Minassian et al. (Aug. 2011) “Transcutaneous spinal cord stimulation,” International Society for Restorative Neurology, http://restorativeneurology.org/resource-center/assessments/transcutaneous-lumbar-spinal-cord-stimulation/; http://restorativeneurology.org/wp-content/uploads/2011/08/Transcutaneous-spinal-cord-stimulation_long.pdf, 6 pp. |
| Minassian et al. (Mar. 2007) “Posterior root-muscle reflexes elicited by transcutaneous stimulation of the human lumbosacral cord,” Muscle & Nerve 35:327-336. |
| Nandra et al., (2014) “Microelectrode Implants for Spinal Cord Stimulation in Rats,” Thesis, California Institute of Technology, Pasadena, California, Defended on Sep. 24, 2014, 104 pages. |
| Nandra et al., (Jan. 23, 2011) “A Parylene-Based Microelectrode Arrary Implant for Spinal Cord Stimulation in Rats,” Conf. Proc. IEEE Eng. Med. Biol. Soc., pp. 1007-1010. |
| Rodger et al., (2007) “High Density Flexible Parylene-Based Multielectrode Arrays for Retinal and Spinal Cord Stimulation,” Transducers & Eurosensors, Proc. of the 14th International Conference on Solid-State Sensors, Actuators and Microsystems, Lyon, France, Jun. 10-14, 2007, IEEE, pp. 1385-1388. |
| Seifert et al. (Nov. 1, 2002) “Restoration of Movement Using Functional Electrical Stimulation and Bayes' Theorem,” The Journal of Neuroscience, 22(1):9465-9474. |
| Tanabe et al. (2008) “Effects of transcutaneous electrical stimulation combined with locomotion-like movement in the treatment of post-stroke gait disorder: a single-case study,” 30(5):411-416 abstract, 1 page. |
| Ward, Alex R. (Feb. 2009) “Electrical Stimulation Using Kilohertz-Frequency Alternating Current ,” (2009) Phys Ther.89(2):181-190 [published online Dec. 18, 2008]. |
| U.S. Final Office Action dated Apr. 19, 2019 issued in U.S. Appl. No. 15/208,529. |
| U.S. Office Action dated Oct. 28, 2019 issued in U.S. Appl. No. 15/208,529. |
| U.S. Notice of Allowance dated Jun. 17, 2020 issued in U.S. Appl. No. 15/208,529. |
| U.S. Office Action dated Jan. 8, 2020 issued in U.S. Appl. No. 15/975,678. |
| U.S. Final Office Action dated Jul. 29, 2020 issued in U.S. Appl. No. 15/975,678. |
| U.S. Office Action dated Oct. 31, 2019 issued in U.S. Appl. No. 15/750,499. |
| U.S. Final Office Action dated Aug. 6, 2020 issued in U.S. Appl. No. 15/750,499. |
| U.S. Office Action dated Jul. 22, 2019 issued in U.S. Appl. No. 15/506,696. |
| U.S. Notice of Allowance dated May 4, 2020 issued in U.S. Appl. No. 15/506,696. |
| U.S. Office Action dated Jun. 4, 2019 issued in U.S. Appl. No. 15/505,053. |
| U.S. Notice of Allowance dated Feb. 13, 2020 issued in U.S. Appl. No. 15/505,053. |
| U.S. 2nd Notice of Allowance dated Jun. 4, 2020 issued in U.S. Appl. No. 15/505,053. |
| U.S. Office Action dated Apr. 7, 2020 issued in U.S. Appl. No. 15/740,323. |
| U.S. Office Action dated Apr. 17, 2019 issued in U.S. Appl. No. 15/344,381. |
| U.S. Final Office Action dated Dec. 30, 2019 issued in U.S. Appl. No. 15/344,381. |
| U.S. Office Action dated Aug. 4, 2020 issued in U.S. Appl. No. 15/344,381. |
| Canadian Office Action dated Jul. 30, 2019 issued in CA 2,864,473. |
| Canadian Office Action dated Aug. 14, 2020 issued in CA 2,864,473. |
| Australian Examination report No. 2 dated Nov. 7, 2019 issued in AU 2014324660. |
| Australian Examination report No. 3 dated Jan. 6, 2020 issued in AU 2014324660. |
| Australian Patent Examination Report No. 1 dated Jan. 6, 2020 issued in AU 2019206059. |
| Canadian Office Action dated May 7, 2020 issued in CA 2,906,779. |
| European Office Action dated Sep. 27, 2019 issued in EP 14765477.6. |
| Australian Patent Examination Report No. 1 dated Jul. 18, 2019 issued in AU 2015308779. |
| Australian Patent Examination Report No. 2 dated May 20, 2020 issued in AU 2015308779. |
| European Extended Search Report dated Apr. 21, 2020 issued in EP 19201998.2. |
| Australian Patent Examination Report No. 1 dated Jun. 14, 2019 issued in AU 2015305237. |
| Australian Patent Examination Report No. 2 dated Apr. 17, 2020 issued in AU 2015305237. |
| European Office Action dated Jul. 17, 2019 issued in EP 15834593.4. |
| European Office Action dated Jul. 30, 2020 issued in EP 15834593.4. |
| European Extended Search Report dated Feb. 19, 2019 issued in EP 16825005.8. |
| Japanese Office Action dated Jul. 13, 2020 issued in JP 2018-501208. |
| PCT International Preliminary Report on Patentability and Written Opinion dated Jul. 30, 2019 issued in PCT/US2018/015098. |
| European Extended Search Report dated Sep. 7, 2020 issued in EP 18744685.1. |
| PCT International Preliminary Report on Patentability and Written Opinion dated Nov. 26, 2019 issued in PCT/US2018/033942. |
| PCT International Search Report and Written Opinion dated Nov. 14, 2019 issued in PCT/US2019/047777. |
| PCT International Search Report and Written Opinion dated Nov. 21, 2019 issued in PCT/US2019/047551. |
| Andersson, et al., (2003) “CNS Involvement in Overactive Bladder.” Drugs, 63(23): 2595-2611. |
| Drummond, et al. (1996) “Thoracic impedance used for measuring chest wall movement in postoperative patients,” British Journal of Anaesthesia, 77: 327-332. |
| Edgerton and Harkema (2011) “Epidural stimulation of the spinal cord in spinal cord injury: current status and future challenges” Expert Rev Neurother. 11(10): 1351-1353. doi:10.1586/ern.11.129 [NIH Public Access—Author Manuscript—5 pages]. |
| Hovey, et al. (2006) “The Guide to Magnetic Stimulation,” The Magstim Company Ltd, 45 pages. |
| Kapetanakis, et al. (2017) “Cauda Equina Syndrome Due to Lumbar Disc Herniation: a Review of Literature,” Folia Medica, 59(4): 377-86. |
| Kondo, et al. (1997) “Laser monitoring of chest wall displacement,” Eur Respir J., 10: 1865-1869. |
| Niu et al., (2018) “A Proof-of-Concept Study of Transcutaneous Magnetic Spinal Cord Stimulation for Neurogenic Bladder,” Scientific Reports, 8: 12549 (12 pages). |
| Szava et al., (Jan. 2011) “Transcutaneous electrical spinal cord stimulation: Biophysics of a new rehabilitation method after spinal cord injury”, ISBN: 978-3-639-34154-6. |
| Wang, et al. (2017) “Incidence of C5 nerve root palsy after cervical surgery,” Medicine, 96(45), 14 pages. |
| U.S. Office Action dated Feb. 10, 2021 issued in U.S. Appl. No. 15/975,678. |
| U.S. Final Office Action dated Nov. 20, 2020 issued in U.S. Appl. No. 15/740,323. |
| U.S. Office Action dated Nov. 13, 2020 issued in U.S. Appl. No. 15/753,963. |
| Australian Examination report No. 1 dated Dec. 21, 2020 issued in AU 2020200152. |
| Canadian Office Action dated Nov. 27, 2020 issued in CA 2,925,754. |
| Chinese First Office Action dated Jan. 6, 2021 issued in CN 201680058067.8. |
| PCT International Search Report and Written Opinion dated Oct. 14, 2020 issued in PCT/US2020/033830. |
| Number | Date | Country | |
|---|---|---|---|
| 20190167987 A1 | Jun 2019 | US |
| Number | Date | Country | |
|---|---|---|---|
| 61883694 | Sep 2013 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 15025201 | US | |
| Child | 16200467 | US |
